glp-1 receptors in the body Physiology of secretion and action on GLP-1 Glucagon-like peptide 1(GLP-1) receptor agonists

5-8 In this regard, it is well recognised that the secretion and action of GIP and GLP-1 is disturbed in obesity and T2D, 5-10,16-18 which could also directly impact skeletal health

You should seek urgent medical advice if you experience: Severe or persistent abdominal pain, which may indicate pancreatitis Persistent vomiting or diarrhoea leading to dehydration Severe headache or visual disturbance, which may suggest pituitary pathology Visual deterioration in the context of diabetes (possible retinopathy) You should also seek medical advice promptly if you: Are currently using or considering using unregulated peptides and experience unexpected symptoms Have noticed unexplained weight changes, fatigue, or hormonal symptoms Are managing a chronic condition such as diabetes, cardiovascular disease, or a hormone-related disorder Have purchased peptides online and are uncertain about their contents or safety Engaging with a qualified healthcare professional whether a GP, endocrinologist, or registered dietitian ensures that any intervention is tailored to your individual health needs, monitored appropriately, and aligned with current evidence

Weight-loss maintenance starts once the active weight-loss phase is over and the patients goal shifts from losing more weight to preventing weight regain

Pen Dosage Chart Dosage & Protocols Variations Standard Research Protocol Dose: 0.02 0.05 mg (= 25 clicks) Duration: 4 6 weeks Frequency: Daily Cycle Interval: 4 weeks off before repeating Goal / Description: Baseline anabolic signaling and muscle growth models

GIP Action: GIP is another incretin hormone that plays a role in glucose-dependent insulin secretion and may also influence fat metabolism and energy expenditure